Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03436264
Other study ID # 0448-17
Secondary ID
Status Recruiting
Phase
First received January 31, 2018
Last updated April 23, 2018
Start date March 1, 2018
Est. completion date December 1, 2019

Study information

Verified date April 2018
Source Rambam Health Care Campus
Contact Eisenberg
Phone 972502061091
Email e_eisenberg@rambam.health.gov.il
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The proneness to react to noxious stimuli varies widely between individuals and pain ratings of seemingly identical noxious stimuli may range from "no pain" to "excruciating pain" . Imaging studies in healthy subjects have provided useful information on the identification of the inter-individual variability in pain perception [2,3,4]. These studies have shown that subjective pain reports are closely related to the degree of neuronal activity in several brain regions known to be identified in pain processing. Furthermore, there has been a growing interest in understanding structural and functional mechanisms of inter-individual variability in responses to identical noxious stimuli [5,6,7]. Yet, the relationship between pain perception and various anatomical and functional connectivity within resting state brain networks is not completely understood. With regard to the anatomical correlate of pain sensitivity, differences in grey matter may reflect neural processes contributing to the construction and modulation of pain in healthy individuals. As such, studies are inconsistent regarding this issue, showing positive [7] or inverse connections [6] between pain sensitivity and brain morphology. The inconsistency regarding this issue warrant further investigation which may elucidate the relationship between differences in pain sensitivity and regional grey matter and may provide novel insights into brain mechanisms contributing to that topic. Understanding brain morphology and connectivity within specific regions associated with pain processing can provide reliable anchor for the individual differences in pain response.

A widely used approach to examine brain morphology from MRI images is voxel based morphometry (VBM). VBM tests for statistically significant differences in regional gray matter (GM) density between study groups, and its temporal changes. Diffusion tensor imaging (DTI) is a type of diffusion weighted imaging with the advantage of being able to resolve individual functional tracts within the white matter (WM) thus, DTI parameters serve as indirect measures of structural connectivity via the degree of integrity of WM tracts.


Description:

Background The proneness to react to noxious stimuli varies widely between individuals and pain ratings of seemingly identical noxious stimuli may range from "no pain" to "excruciating pain" . Imaging studies in healthy subjects have provided useful information on the identification of the inter-individual variability in pain perception [2,3,4]. These studies have shown that subjective pain reports are closely related to the degree of neuronal activity in several brain regions known to be identified in pain processing. Furthermore, there has been a growing interest in understanding structural and functional mechanisms of inter-individual variability in responses to identical noxious stimuli [5,6,7]. Yet, the relationship between pain perception and various anatomical and functional connectivity within resting state brain networks is not completely understood. With regard to the anatomical correlate of pain sensitivity, differences in grey matter may reflect neural processes contributing to the construction and modulation of pain in healthy individuals. As such, studies are inconsistent regarding this issue, showing positive [7] or inverse connections [6] between pain sensitivity and brain morphology. The inconsistency regarding this issue warrant further investigation which may elucidate the relationship between differences in pain sensitivity and regional grey matter and may provide novel insights into brain mechanisms contributing to that topic. Understanding brain morphology and connectivity within specific regions associated with pain processing can provide reliable anchor for the individual differences in pain response.

A widely used approach to examine brain morphology from MRI images is voxel based morphometry (VBM). VBM tests for statistically significant differences in regional gray matter (GM) density between study groups, and its temporal changes. Diffusion tensor imaging (DTI) is a type of diffusion weighted imaging with the advantage of being able to resolve individual functional tracts within the white matter (WM) thus, DTI parameters serve as indirect measures of structural connectivity via the degree of integrity of WM tracts.

2. Aim of the study To Identify neuroimaging biomarkers, demographic, personality and sensory factors for predicting extreme pain responses to various experimental pain stimulations in healthy subjects 3. Methods 3.1 Sample

The study population will consist of 196 healthy participants. Of these, 48 patients will undergo brain imaging after meeting the following inclusion and exclusion criteria:

Study design The proposed study has been conducted at the Pain Research Laboratory of University of Haifa (in which psychophysics tests will be conducted), and imaging tests will be performed at the Imaging department of Rambam Health Care Campus.

Subjects were recruited through advertisements distributed on campus bulletin board. Responders who met the inclusion criteria were invited to participate in the study. The trial will be held in two independent experimental sessions with an estimated duration of one hour and a half for the psychophysical tests and half an hour for the neuroimaging session.

This study is focused on extreme subgroups only. Therefore, in the first session (which took place in the pain lab) subjects (n=196) were either divided into two subgroups according to their tolerance results to the Cold Pressor Test (CPT) (high tolerance subgroup = 180 s vs. low tolerance subgroup ≤20 s). 24 subjects from each subgroup will be randomly selected and will receive an explanation about the option to participate in the brain imaging test. Subjects who will decide to participate in the imaging test will undergo it at the Imaging Department of Rambam Health Care Campus. Upon arrival, subjects will receive a full explanation of the course and time of the MRI scan of the brain and will be asked to sign an informed consent form. The duration time of the MRI procedure is around half an hour during which no material will be injected or pain tests will be performed.

During the test, several sequences will be performed; three-dimensional high-resolution anatomy, another structural test for the definition of connectivity (DTI), and resting state (RS) fMRI tests to examine the activity of brain networks. MRI will be performed using a 3-Tesla scanner (GE Discovery MR750). The protocol consists of (1) a T1-weighted 3D magnetization-prepared rapid gradient echo (MPRAGE) sequence (176 slices; 220 × 220 matrix; TR = 2520 ms; TE = 1.74 ms; 1.0 × 1.0 × 1.0 mm voxels), (2) an echo-planar imaging (EPI) resting state sequence (34 slices; TR = 2010 ms; TE = 30 ms; 64 × 64 matrix; 3.5 × 3.5 × 5 mm voxels 200 volumes lag=4 RTs), (3) a diffusion-weighted imaging (DTI) sequence (70 slices; TR = 4600 ms; TE = 89 ms; 2 × 2 × 2 mm voxels) using non-collinear 64 directions and a single non-diffusion weighted (b = 0 s/mm2) image. At the end of the examination, analyzes of the data will be carried out for each individual and for each population of the study. After the MRI scan subjects will be asked to fill out the depression, anxiety and stress scales (DASS): The DASS assess depression, anxiety and stress with 7 Items each (Henry & Crawford, 2005). The DASS-Depression focuses on reports of low mood, motivation, and self-esteem, DASS-anxiety on physiological arousal, perceived panic, and fear, and DASS-stress on tension and irritability. The short‐form version of the Depression Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a large non‐clinical sample. It was validated in a population of over 300 patients with chronic pain as well as healthy volunteers and found valid and reliable in both populations.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date December 1, 2019
Est. primary completion date December 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Healthy males and females, over the age of 18, free from chronic pain of any type.

2. No medication use (except for oral contraceptives).

3. Able to understand the purpose and instructions of the study and to sign an informed consent.

Exclusion Criteria:

1. Pregnant women

2. Inability to comply with study protocol.

3. A diagnosis of Raynaud's Syndrome

4. Subjects with metal implants of any kind (including pace maker) and Claustrophobia will be excluded from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRI
fMRI

Locations

Country Name City State
Israel Rambam Health Care Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary fMRI diffrences a. Both subgroups will demonstrate differences in gray matter density and cortical thickness in key cortical regions that are responsible for the processing and modulation of sensory stimuli, such as primary somatosensory cortex (S1), cingulate cortex (ACC/MCC/PCC), prefrontal cortex (PFC including OFC) and insula. 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care